Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LATS1 | O95835 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504998 | 0.83 | NPC1 (0.46) | POLBNPC1RAB9AMAPTMEN1 | |
| SCHEMBL3459588 | 0.81 | POLB (0.46) | POLBNPC1RAB9AMAPTLATS1 | |
| SCHEMBL24392349 | 0.81 | PDGFRB (0.52) | NPC1RAB9AMAPTLATS1KDM4E | |
| SCHEMBL15483468 | 0.79 | MAPT (0.67) | POLBMAPTLATS1KDM4EALDH1A1 | |
| SCHEMBL27912718 | 0.78 | POLB (0.43) | POLBNPC1RAB9AMAPTLATS1 | |
| SCHEMBL3461416 | 0.77 | MAPT (0.59) | POLBMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL15645641 | 0.77 | LATS1 (0.61) | LATS1LATS2 | |
| SCHEMBL29589358 | 0.76 | WHR1 (0.54) | NPC1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL3469022 | 0.76 | WHR1 (0.54) | NPC1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL27694108 | 0.75 | CYP1A2 (0.53) | POLBNPC1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1610774-A4 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1610774-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004092196-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | POLB 3691/4885NPC1 4467/4885RAB9A 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.